Literature DB >> 20478652

Original Gleason system versus 2005 ISUP modified Gleason system: the importance of indicating which system is used in the patient's pathology and clinical reports.

Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, Roberta Mazzucchelli, Gregor Mikuz, Ziya Kirkali, Francesco Montorsi.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20478652     DOI： 10.1016/j.eururo.2010.04.028

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  11 in total

1.  Prostate cancer: Effects of tertiary Gleason pattern 5 on oncological outcome.

Authors:  Sean R Williamson; Liang Cheng
Journal:  Nat Rev Urol       Date:  2015-01-20       Impact factor: 14.432

2.  The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literature.

Authors:  A Offermann; M C Hupe; V Sailer; A S Merseburger; S Perner
Journal:  World J Urol       Date:  2019-04-02       Impact factor: 4.226

3.  Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

Authors:  Jennifer Cullen; Denise Young; Yongmei Chen; Michael Degon; James Farrell; Jason Sedarsky; Wagner Baptiste; Philip Rosen; Vladimir Tolstikov; Michael Kiebish; Jacob Kagan; Sudhir Srivastava; Huai-Ching Kuo; Joel T Moncur; Inger L Rosner; Niven Narain; Viatcheslav Akmaev; Gyorgy Petrovics; Albert Dobi; David G McLeod; Shiv Srivastava; Isabell A Sesterhenn
Journal:  Eur Urol Focus       Date:  2017-03-11

Review 4.  Does true Gleason pattern 3 merit its cancer descriptor?

Authors:  Saiful Miah; Hashim U Ahmed; Alex Freeman; Mark Emberton
Journal:  Nat Rev Urol       Date:  2016-08-17       Impact factor: 14.432

5.  Gleason grade progression is uncommon.

Authors:  Kathryn L Penney; Meir J Stampfer; Jaquelyn L Jahn; Jennifer A Sinnott; Richard Flavin; Jennifer R Rider; Stephen Finn; Edward Giovannucci; Howard D Sesso; Massimo Loda; Lorelei A Mucci; Michelangelo Fiorentino
Journal:  Cancer Res       Date:  2013-08-15       Impact factor: 12.701

Review 6.  Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned.

Authors:  Lisa M Lowenstein; Spyridon P Basourakos; Michelle D Williams; Patricia Troncoso; Justin R Gregg; Timothy C Thompson; Jeri Kim
Journal:  Nat Rev Clin Oncol       Date:  2019-03       Impact factor: 66.675

7.  Clinicopathologic features of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens.

Authors:  Berna Aytac; Hakan Vuruskan
Journal:  World J Surg Oncol       Date:  2011-07-20       Impact factor: 2.754

8.  Novel concepts for risk stratification in prostate cancer.

Authors:  Keval M Patel; Vincent J Gnanapragasam
Journal:  J Clin Urol       Date:  2016-12-01

9.  Significant association between the Axin2 rs2240308 single nucleotide polymorphism and the incidence of prostate cancer.

Authors:  Chao Ma; Chunxiao Liu; Peng Huang; Haruki Kaku; Jie Chen; Kai Guo; Hideo Ueki; Akiko Sakai; Yasutomo Nasu; Hiromi Kumon; Kenji Shimizu; Masami Watanabe
Journal:  Oncol Lett       Date:  2014-05-26       Impact factor: 2.967

Review 10.  Targeting the cancer lesion, not the whole prostate.

Authors:  Nishant Bedi; Deepika Reddy; Hashim U Ahmed
Journal:  Transl Androl Urol       Date:  2020-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.